Tarsier Pharma Upsizes IPO to Raise Nearly $50 Million
Israel-based Tarsier Pharma (TARX) has upsized its initial public offering in the U.S., aiming to raise nearly $50 million. The biopharma company, which focuses on eye disease treatments, filed for an increased IPO this week.
Topics: biotech ipo pharmaceuticals